Dermira Prices Follow-On Public Offering of Common Stock

MENLO PARK, Calif., Aug. 5, 2015 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ: DERM), a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists and their patients, today announced the pricing of its follow-on public offering of 4,500,000 shares of its common stock at a price to the public of $21.50 per share. In addition, Dermira has granted the underwriters a 30-day option to purchase up to an additional 675,000 shares of its common stock, on the same terms and conditions.

Leerink Partners LLC, Cowen and Company and Guggenheim Securities are acting as joint book-running managers for the offering. Needham & Company is acting as co-manager.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on August 5, 2015. This offering is being made solely by means of a prospectus, copies of which, when available, may be obtained from Leerink Partners LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, by email at [email protected], or by telephone at 1-800-808-7525, ext. 6142, Cowen and Company, c/o Broadridge Financial Services, Attention: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, Telephone: 631-274-2806 or Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, telephone 212-518-9658 or by email to [email protected].

CONTACT: Dermira Contact
         Andrew Guggenhime
         Chief Operating Officer and Chief Financial Officer
         650.421.7200
         [email protected]

         Investor Contact
         Westwicke Partners
         Robert H. Uhl
         Managing Director
         858.356.5932
         [email protected]

You May Also Be Interested In

• Men’s Wearhouse owner Tailored Brands, bankrupt in 2020, files for IPO
• Nu-Med Plus acquires Avid Gold, targets Canadian gold properties
• Alpha and Omega Semiconductor appoints Joshua Chien to its board